Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules/( G.D. Searle, Inc) Under Fed Conditions

NCT01380522 is registered in ClinicalTrials.gov with Par Pharmaceutical, Inc. as lead sponsor.

NCT NCT01380522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01380522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules/( G.D. Searle, Inc) Under Fed Conditions
Lead sponsor
Par Pharmaceutical, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2002
Completion date
September 30, 2002
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

to determine the bioequivalence study under fed